Structured Review

Abbott Laboratories abbott realtime hcv rna
Abbott Realtime Hcv Rna, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abbott realtime hcv rna/product/Abbott Laboratories
Average 85 stars, based on 1 article reviews
Price from $9.99 to $1999.99
abbott realtime hcv rna - by Bioz Stars, 2020-05
85/100 stars

Related Products / Commonly Used Together

hcv rna

Images

Related Articles

other:

Article Title: Characterization of HIV-HBV co-infection in a multi-national HIV-infected cohort
Article Snippet: HCV RNA was determined with the Abbott RealTime HCV RNA (Abbott Molecular, Des Plaines, IL), performed according to manufacturer’s instructions.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Abbott Laboratories hcv rna
    Distribution of <t>HCV-RNA</t> (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).
    Hcv Rna, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcv rna/product/Abbott Laboratories
    Average 94 stars, based on 45 article reviews
    Price from $9.99 to $1999.99
    hcv rna - by Bioz Stars, 2020-05
    94/100 stars
      Buy from Supplier

    86
    Abbott Laboratories licensed abbott realtime hcv assay
    Addition of HTEIs to DAA prevents the emergence of DAA-resistant variants. (A) Huh7.5.1 cells were transfected with RNA encoding wild-type <t>HCV</t> Jc1 and plated in the presence of 1% DMSO and treated with anti-CLDN1 mAb (10 µg/mL), simeprevir (500 nM) alone or in combination with anti-CLDN1 mAb (10 µg/mL) or in the absence of treatment (CTRL). The combination treatment was stopped on day 51 while anti-CLDN1 mAb and simeprevir in monotherapy continued until day 58. Viral load was assessed by RT-PCR every 3–4 days. The limit of quantification (LOQ), indicated by a dashed line, was 10 3 copies/mL. The experiment was performed in triplicate and repeated twice. Among the detected triplicate samples, one out of three was HCV RNA negative on day 27 (empty circle under the LOQ), two out of three negative on day 30 (empty circles under the LOQ), three out of three negative from day 37 on. The undetectable HCV load from day 40 was confirmed by a clinically licensed HCV RNA detection assay, the Abbott <t>RealTime</t> HCV assay (Abbott), and is indicated by a star (LOD of Abbott qRT-PCR is 48 IU/mL with 250 µL liquid sample). (B) A similarly designed experiment was performed using anti-SR-BI mAb NK-8H5-E3 instead of anti-CLDN1 mAb. (C) Combination of daclatasvir and simeprevir fails to clear HCV genotype 2 infection. Using the same assay as described above, the cells were treated with 5 nM daclatasvir, 500 nM simeprevir, combination of 5 nM daclatasvir and 500 nM simeprevir or mock (CTRL). Viral load was assessed by RT-PCR every 3–4 days. Means ± SD from a representative experiment performed in triplicate are shown.
    Licensed Abbott Realtime Hcv Assay, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/licensed abbott realtime hcv assay/product/Abbott Laboratories
    Average 86 stars, based on 15 article reviews
    Price from $9.99 to $1999.99
    licensed abbott realtime hcv assay - by Bioz Stars, 2020-05
    86/100 stars
      Buy from Supplier

    88
    Abbott Laboratories plasma hcv rna level
    <t>HCV</t> epidemiology and disease burden in areas with high and moderate HCV prevalence in Thailand. Samples recruited from Phetchabun (n = 1667) and Khon Kaen (n = 1410) were screened for anti-HCV antibodies (upper panel). Among all anti-HCV antibody-positive individuals, HCV <t>RNA</t> positive (RNA positive sample in the follow-up study is indicated in a dashed circle), eligibility for universal coverage (according to the NHSO requirements) and hepatic fibrosis were all evaluated (lower panel). The NHSO criteria for HCV treatment reimbursement were TE ≥7.5 kPa and viral load ≥5000 IU/mL. The advanced liver disease was represented by liver stiffness > 9.5 kPa or a fibrosis score (METAVIR stage F3-F4). The proportion of individuals in each category is indicated by the size of the circle diagrams.
    Plasma Hcv Rna Level, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 88/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma hcv rna level/product/Abbott Laboratories
    Average 88 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    plasma hcv rna level - by Bioz Stars, 2020-05
    88/100 stars
      Buy from Supplier

    Image Search Results


    Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

    Journal: BMC Infectious Diseases

    Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

    doi: 10.1186/1471-2334-14-222

    Figure Lengend Snippet: Distribution of HCV-RNA (A) and HCVAg (B) by HCV genotype. Significant differences between median values were observed only between genotypes 1 and 3 for both HCV-RNA (p = 0.028) and HCVAg (p = 0.0098).

    Article Snippet: 355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes.

    Techniques:

    Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

    Journal: BMC Infectious Diseases

    Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

    doi: 10.1186/1471-2334-14-222

    Figure Lengend Snippet: Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA > 12 IU/ml. Values are reported on a logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.

    Article Snippet: 355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes.

    Techniques:

    Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

    Journal: BMC Infectious Diseases

    Article Title: HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

    doi: 10.1186/1471-2334-14-222

    Figure Lengend Snippet: Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3 A and B were almost identical whereas the patient in Figure 3 C showed a persistence of HCVAg positivity and a virological relapse on the following draw. Dotted line: HCVAg; solid line: HCV-RNA.

    Article Snippet: 355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes.

    Techniques: Infection

    Addition of HTEIs to DAA prevents the emergence of DAA-resistant variants. (A) Huh7.5.1 cells were transfected with RNA encoding wild-type HCV Jc1 and plated in the presence of 1% DMSO and treated with anti-CLDN1 mAb (10 µg/mL), simeprevir (500 nM) alone or in combination with anti-CLDN1 mAb (10 µg/mL) or in the absence of treatment (CTRL). The combination treatment was stopped on day 51 while anti-CLDN1 mAb and simeprevir in monotherapy continued until day 58. Viral load was assessed by RT-PCR every 3–4 days. The limit of quantification (LOQ), indicated by a dashed line, was 10 3 copies/mL. The experiment was performed in triplicate and repeated twice. Among the detected triplicate samples, one out of three was HCV RNA negative on day 27 (empty circle under the LOQ), two out of three negative on day 30 (empty circles under the LOQ), three out of three negative from day 37 on. The undetectable HCV load from day 40 was confirmed by a clinically licensed HCV RNA detection assay, the Abbott RealTime HCV assay (Abbott), and is indicated by a star (LOD of Abbott qRT-PCR is 48 IU/mL with 250 µL liquid sample). (B) A similarly designed experiment was performed using anti-SR-BI mAb NK-8H5-E3 instead of anti-CLDN1 mAb. (C) Combination of daclatasvir and simeprevir fails to clear HCV genotype 2 infection. Using the same assay as described above, the cells were treated with 5 nM daclatasvir, 500 nM simeprevir, combination of 5 nM daclatasvir and 500 nM simeprevir or mock (CTRL). Viral load was assessed by RT-PCR every 3–4 days. Means ± SD from a representative experiment performed in triplicate are shown.

    Journal: PLoS Pathogens

    Article Title: Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents

    doi: 10.1371/journal.ppat.1004128

    Figure Lengend Snippet: Addition of HTEIs to DAA prevents the emergence of DAA-resistant variants. (A) Huh7.5.1 cells were transfected with RNA encoding wild-type HCV Jc1 and plated in the presence of 1% DMSO and treated with anti-CLDN1 mAb (10 µg/mL), simeprevir (500 nM) alone or in combination with anti-CLDN1 mAb (10 µg/mL) or in the absence of treatment (CTRL). The combination treatment was stopped on day 51 while anti-CLDN1 mAb and simeprevir in monotherapy continued until day 58. Viral load was assessed by RT-PCR every 3–4 days. The limit of quantification (LOQ), indicated by a dashed line, was 10 3 copies/mL. The experiment was performed in triplicate and repeated twice. Among the detected triplicate samples, one out of three was HCV RNA negative on day 27 (empty circle under the LOQ), two out of three negative on day 30 (empty circles under the LOQ), three out of three negative from day 37 on. The undetectable HCV load from day 40 was confirmed by a clinically licensed HCV RNA detection assay, the Abbott RealTime HCV assay (Abbott), and is indicated by a star (LOD of Abbott qRT-PCR is 48 IU/mL with 250 µL liquid sample). (B) A similarly designed experiment was performed using anti-SR-BI mAb NK-8H5-E3 instead of anti-CLDN1 mAb. (C) Combination of daclatasvir and simeprevir fails to clear HCV genotype 2 infection. Using the same assay as described above, the cells were treated with 5 nM daclatasvir, 500 nM simeprevir, combination of 5 nM daclatasvir and 500 nM simeprevir or mock (CTRL). Viral load was assessed by RT-PCR every 3–4 days. Means ± SD from a representative experiment performed in triplicate are shown.

    Article Snippet: Most interestingly, during combination treatment, HCV RNA became undetectable by qualitative RT-PCR and using the clinically licensed Abbott RealTime HCV assay (Abbott) with a limit of detection of 48 IU/mL ( ).

    Techniques: Transfection, Reverse Transcription Polymerase Chain Reaction, RNA Detection, Quantitative RT-PCR, Infection

    HCV epidemiology and disease burden in areas with high and moderate HCV prevalence in Thailand. Samples recruited from Phetchabun (n = 1667) and Khon Kaen (n = 1410) were screened for anti-HCV antibodies (upper panel). Among all anti-HCV antibody-positive individuals, HCV RNA positive (RNA positive sample in the follow-up study is indicated in a dashed circle), eligibility for universal coverage (according to the NHSO requirements) and hepatic fibrosis were all evaluated (lower panel). The NHSO criteria for HCV treatment reimbursement were TE ≥7.5 kPa and viral load ≥5000 IU/mL. The advanced liver disease was represented by liver stiffness > 9.5 kPa or a fibrosis score (METAVIR stage F3-F4). The proportion of individuals in each category is indicated by the size of the circle diagrams.

    Journal: PLoS ONE

    Article Title: Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study

    doi: 10.1371/journal.pone.0196301

    Figure Lengend Snippet: HCV epidemiology and disease burden in areas with high and moderate HCV prevalence in Thailand. Samples recruited from Phetchabun (n = 1667) and Khon Kaen (n = 1410) were screened for anti-HCV antibodies (upper panel). Among all anti-HCV antibody-positive individuals, HCV RNA positive (RNA positive sample in the follow-up study is indicated in a dashed circle), eligibility for universal coverage (according to the NHSO requirements) and hepatic fibrosis were all evaluated (lower panel). The NHSO criteria for HCV treatment reimbursement were TE ≥7.5 kPa and viral load ≥5000 IU/mL. The advanced liver disease was represented by liver stiffness > 9.5 kPa or a fibrosis score (METAVIR stage F3-F4). The proportion of individuals in each category is indicated by the size of the circle diagrams.

    Article Snippet: Laboratory tests To assess HCV-associated liver injury severity, the subjects were tested for clinical parameters including re-testing for anti-HCV antibodies (ARCHITECT, Abbott Diagnostics, Wiesbaden, Germany), liver enzymes (aspartate transaminase [AST] and alanine transaminase [ALT]) and plasma HCV-RNA level (Abbott RealTime HCV assay, Abbott Molecular, IL, USA).

    Techniques: